Heart attack medication, clinical diagnosis
Reading File
Now I'll search the medical library for heart attack (MI) clinical diagnosis and medications simultaneously.
Finding Sources
Finding Sources
Searching PubMed
"myocardial infarction" AND "treatment guidelines"
Good. Now let me read the key sections from Goldman-Cecil Medicine on STEMI and also search for NSTEMI/ACS management and pharmacotherapy.
Finding Sources
Finding Sources
Excellent - Rosen's Emergency Medicine has a dedicated ACS medications table. Let me read that section plus search for STEMI-specific management content.
Reading File
Reading File
I found the ACS medications table in block11. Let me read that specific section more carefully, plus the clinical diagnosis section.
Reading File
I got a wealth of detailed content from the ACS medications table and the clinical sections. Let me now compile this into a comprehensive answer.
Reading File
I now have comprehensive content. Let me provide a thorough, well-organized answer.
Heart Attack (Myocardial Infarction): Clinical Diagnosis & Medications
Overview
A heart attack (myocardial infarction, MI) results from sustained ischemia causing irreversible myocardial cell death, most commonly due to acute plaque rupture with superimposed thrombosis in a coronary artery. The clinical spectrum is divided into:
- STEMI (ST-Elevation MI) - complete occlusion, immediate reperfusion required
- NSTEMI (Non-ST-Elevation MI) - partial occlusion, elevated troponin without ST elevation
- Unstable Angina (UA) - partial occlusion, no troponin rise
Together these are called Acute Coronary Syndromes (ACS).
Part 1: Clinical Diagnosis
Symptoms
| Symptom | Notes |
|---|---|
| Chest pain/pressure | Often described as "crushing," "heavy," or "squeezing" - may radiate to jaw, left arm, or back |
| Diaphoresis | Cold, clammy sweat - an autonomic response |
| Dyspnea | Especially in anterior MI or LV dysfunction |
| Nausea/vomiting | Common, especially in inferior MI (vagal response) |
| Syncope/presyncope | May indicate serious arrhythmia or cardiogenic shock |
Atypical presentations are common in women, diabetics, and the elderly - they may present with fatigue, epigastric discomfort, or absence of chest pain entirely.
ECG Findings
STEMI criteria:
- ST elevation ≥1 mm in ≥2 contiguous limb leads
- ST elevation ≥2 mm in ≥2 contiguous precordial leads (V1-V6)
- New left bundle branch block (LBBB) is treated as STEMI equivalent
- Posterior MI: ST depression in V1-V3 + tall R waves (mirror image)
Localization by ECG:
| Territory | Leads Affected | Artery |
|---|---|---|
| Anterior | V1-V4 | LAD |
| Lateral | I, aVL, V5-V6 | LCx |
| Inferior | II, III, aVF | RCA |
| Posterior | V1-V3 (reciprocal changes) | RCA/LCx |
NSTEMI/UA shows ST depression, T-wave inversions, or may have a normal ECG.
Serum Biomarkers
Cardiac Troponin (I or T) is the gold standard:
- Rises within 2-4 hours of onset
- Peaks at 12-24 hours
- Returns to baseline in 7-14 days (troponin I) or up to 14 days (troponin T)
- High-sensitivity troponin (hs-Tn) allows earlier rule-in/rule-out (within 1-3 hours)
- Serial measurements (0h, 1h or 0h, 3h) are used in modern accelerated diagnostic protocols
CK-MB:
- Less specific than troponin
- Rises at 4-6 hours, peaks at 12-24h, returns to normal in 36-72h
- Still useful for detecting reinfarction (as troponin remains elevated)
Myoglobin:
- Earliest marker (rises in 1-2h) but highly non-specific
Clinical Decision Rules for Risk Stratification
- HEART Score (History, ECG, Age, Risk factors, Troponin) - widely used in ED
- EDACS-ADP - Emergency Department Assessment of Chest pain Score
- TIMI Risk Score - for NSTEMI/UA prognosis
- GRACE Score - predicts in-hospital and 6-month mortality in ACS
Imaging
- Echo (TTE/TEE): Detects wall motion abnormalities, LV function, mechanical complications
- Coronary CTA: Useful for ruling out ACS in low-intermediate risk patients
- Nuclear scintigraphy / stress testing: For stable intermediate-risk patients after rule-out
Part 2: Medications
Emergency/Acute Phase (ED Management)
The classic mnemonic: MONA (Morphine, Oxygen, Nitrates, Aspirin) - though oxygen is now reserved for hypoxia (SpO₂ <90%).
1. Antiplatelets
| Drug | Dose | Notes |
|---|---|---|
| Aspirin | 162-325 mg chewed immediately | First-line for all ACS; irreversibly inhibits COX-1, blocks TXA₂-mediated platelet aggregation |
| Clopidogrel (P2Y12 blocker) | 600 mg loading dose for PCI; 300 mg for fibrinolysis | Prodrug, requires CYP2C19 activation; delayed onset |
| Ticagrelor | 180 mg loading dose | Preferred over clopidogrel for STEMI/NSTEMI; reversible, faster onset; do NOT use with fibrinolytics |
| Prasugrel | 60 mg loading dose | Potent P2Y12 blocker; avoid in prior stroke/TIA, age >75, weight <60 kg |
Dual antiplatelet therapy (DAPT = aspirin + P2Y12 inhibitor) is standard for all ACS.
2. Anticoagulants
| Drug | Notes |
|---|---|
| UFH (Unfractionated Heparin) | Preferred for STEMI going to PCI (faster onset, easily reversible with protamine); 60 units/kg IV bolus (max 4000 units) + infusion |
| Enoxaparin (LMWH) | 1 mg/kg SC twice daily; preferred for conservative NSTEMI management; reduce to 1 mg/kg daily if GFR <30 mL/min; UFH preferred for immediate PCI |
| Bivalirudin | Direct thrombin inhibitor; used as alternative to heparin during PCI; reduces bleeding risk |
| Fondaparinux | Factor Xa inhibitor; preferred for medically managed NSTEMI when PCI not planned; NOT for primary PCI (risk of catheter thrombus) |
3. Nitrates
- Nitroglycerin (sublingual or IV): Vasodilation reduces preload and ischemic pain; contraindicated if SBP <90 mmHg, severe bradycardia, right ventricular infarction, or recent PDE5 inhibitor use (sildenafil within 24h, tadalafil within 48h)
4. Beta-Blockers
- Metoprolol, atenolol, carvedilol
- Reduce HR, contractility, and O₂ demand; reduce arrhythmias; decrease mortality post-MI
- Contraindicated in: acute decompensated HF, cardiogenic shock, severe bradycardia (HR <60), high-degree AV block, active bronchospasm
- Oral beta-blocker should be initiated within 24 hours if no contraindications; IV form only for refractory hypertension or tachyarrhythmia
5. GP IIb/IIIa Inhibitors
- Abciximab, eptifibatide, tirofiban
- Block fibrinogen binding to GP IIb/IIIa receptor on platelets
- Used adjunctively during PCI, especially with large thrombus burden
- Eptifibatide/tirofiban: small-molecule; abciximab: monoclonal antibody fragment
6. Oxygen
- Only for hypoxic patients (SpO₂ <90%); routine supplemental O₂ in normoxic patients is no longer recommended and may be harmful
7. Opioid Analgesia
- Morphine (2-4 mg IV): For refractory pain; associated with delayed clopidogrel absorption - use with caution
Post-MI / Long-Term Medications
| Drug Class | Drugs | Indication |
|---|---|---|
| ACE inhibitor / ARB | Lisinopril, ramipril, valsartan | Start within 24h in STEMI, especially with LV dysfunction (EF <40%), anterior MI, or HF; reduce remodeling and mortality |
| Statin (high-intensity) | Atorvastatin 80 mg, rosuvastatin 40 mg | Start immediately in all ACS patients regardless of baseline LDL; pleiotropic effects beyond LDL lowering |
| Beta-blocker | Metoprolol succinate, carvedilol | Long-term therapy for LV dysfunction; continue for at least 1-3 years post-MI |
| Aldosterone antagonist | Eplerenone, spironolactone | Post-MI with EF ≤40% and either HF or diabetes; avoid if K⁺ >5.0 or GFR <30 |
| DAPT | Aspirin + P2Y12 inhibitor | Continue for 12 months post-ACS (both stent and non-stent); duration may be modified based on bleeding vs. ischemic risk |
Reperfusion Therapy
This is the cornerstone of STEMI management:
- Primary PCI (percutaneous coronary intervention): Gold standard - balloon/stent across the culprit lesion; target door-to-balloon time ≤90 minutes; every 30-minute delay increases 12-month mortality by 7.5%
- Fibrinolysis (thrombolytics): If PCI not available within 120 min of first medical contact; give within 30 minutes of arrival; agents include alteplase (tPA), tenecteplase (TNK), reteplase (rPA)
- Fibrinolysis contraindications: Prior intracranial hemorrhage, ischemic stroke <3 months, active internal bleeding, aortic dissection, severe uncontrolled hypertension
Summary Table: ACS Drug Overview (from Rosen's Emergency Medicine)
| Medication Class | Examples | Indication | Key Risks |
|---|---|---|---|
| Antiplatelet | Aspirin, clopidogrel, ticagrelor, prasugrel | All ACS | Bleeding, GI upset |
| Anticoagulant | UFH, enoxaparin, bivalirudin, fondaparinux | All ACS | Bleeding, HIT (UFH) |
| Nitrate | Nitroglycerin | Ischemic pain, HF | Hypotension; CI in RV infarct, PDE5 use |
| Beta-blocker | Metoprolol, atenolol | Rate control, arrhythmia, anti-ischemic | Bradycardia, bronchospasm, cardiogenic shock |
| GP IIb/IIIa inhibitor | Abciximab, eptifibatide, tirofiban | High-risk PCI | Bleeding, thrombocytopenia |
| ACE-I / ARB | Lisinopril, valsartan | Post-MI, LV dysfunction | Hypotension, hyperkalemia, renal impairment |
| Statin | Atorvastatin 80 mg | All ACS, long-term | Myopathy, hepatotoxicity (rare) |
| Aldosterone antagonist | Eplerenone | Post-MI with EF ≤40% | Hyperkalemia |
Sources: Rosen's Emergency Medicine, 10th Ed. - Chapter 64 (ACS); Goldman-Cecil Medicine, 26th Ed.; Braunwald's Heart Disease, 12th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.